Docket No.: AM101204 US/WYNC-0328

Application No.: 10/659,160

NE12-

Office Action Dated: November 24, 2004

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. (original) A compound of Formula I:

$$\begin{array}{c|c}
R^1 & O & (CH_2)_n & R^2 \\
X & V & O & I
\end{array}$$

wherein

R¹, R² and R³ are, independently, hydrogen, hydroxy, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkanoyl of 2 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, alkanesulfonyl of 1 to 6 carbon atoms or alkanesulfonamido of 1 to 6 carbon atoms;

X and Y are, independently, hydrogen, hydroxy, halo, cyano, carboxamido, earboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkanoyl of 2 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which cach alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, alkanesulfonyl of 1 to 6 carbon atoms or alkanesulfonamido of 1 to 6 carbon atoms, or X- and Y_{λ} taken together, form $-N = C(R^4) \cdot C(R^5) = N$, $-N = C(R^4) \cdot C(R^6) = CH$ -, $-N = C(R^4) \cdot C(R^6$

R⁴ and R⁵ are; independently, hydrogen, halo, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms or alkyl of 1 to 6 carbon atoms;

R⁶ is hydrogen or alkyl of 1 to 6 carbon atoms;

Application No.: 10/659,160

Office Action Dated: November 24, 2004

R⁷ is hydrogen, halo, trifluoromethyl, pentafluoroethyl, amino, mono- or dialkylamino in which each alkyl-group has 1 to 6 carbon atoms, or alkyl-of 1 to 6 carbon atoms;

R⁸ is hydrogen, halo, trifluoromethyl, pentafluoroethyl, or alkyl of 1 to 6 earbon atoms;

the dotted line represents an optional double bond;

Z is oxygen or sulfur;

Q is carbon or nitrogen; and

n is 0 or 1;

or a pharmaceutically acceptable salt thereof.

2. (original) A compound according to claim 1, wherein Q is carbon and Z is S.

3. (original) A compound according to claim 1, wherein X and Y taken together form -N=C(R⁴)-C(R⁶)=CH- or -NH-C(R⁸)=CH-.

3 4. (original) A compound according to claim 1 having Formula Ia:

$$R^1$$
 O
 N
 R^2
 R^4
 R^6

Ia

or a pharmaceutically acceptable salt thereof.

4 %. (original) A compound according to claim 1, wherein R⁶ is hydrogen or alkyl of 1 to 3 carbon atoms.

6. (withdrawn) A compound according to claim 1 having Formula Ib

Docket No.: AM101204 US/WYNC-0328

Application No.: 10/659,160

Office Action Dated: November 24, 2004

or a pharmaceutically acceptable salt thereof.

- 5 1/2. (original) A compound according to claim 1, wherein R¹ is hydrogen, halo, cyano, trifluoromethyl, alkyl of 1 to 6 carbon atoms or alkoxy of 1 to 6 carbon atoms.
- (original) A compound according to claim 1, wherein R¹ is hydrogen, halo or alkoxy of 1 to 6 carbon atoms.
- 7 %. (original) A compound according to claim 1, wherein R¹ is hydrogen.
- (independently selected from hydrogen, hydroxy, halo, cyano, carboxamido, alkyl of 1 to 6 carbon atoms, or alkoxy of 1 to 6 carbon atoms.
- 9 M. (original) A compound according to claim 1, wherein R² and R³ are independently selected from hydrogen, cyano or halogen.
- (0 V2. (original) A compound according to claim 1, wherein R⁴ and R⁵ are independently hydrogen, amino or alkyl of 1 to 6 carbon atoms.
- 1/3. (original) A compound according to claim 1, wherein R⁴ and R⁵ are independently hydrogen or alkyl of 1 to 3 carbon atoms.

Docket No.: AM101204 US/WYNC-0328

Application No.: 10/659,160

Office Action Dated: November 24, 2004

14. (original) A compound according to claim 1, wherein R⁷ and R⁸ are independently selected from hydrogen, trifluoromethyl, pentafluoroethyl or alkyl of 1 to 6 carbon atoms.

- 15. (original) A compound according to claim 1, wherein R⁷ and R⁸ are independently hydrogen, trifluoromethyl or alkyl of 1 to 3 carbon atoms.
- 12 16. (original) A compound according to claim 1, wherein n is 0 and the dotted line represents a double bond.
- 13 V1. (original) A compound according to claim 1, wherein said compound is 2-(4-benzo[b]thiophen-3-yl-3,6-dihydro-2H-pyridin-1-ylmethyl)-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
- benzo[b]thiophen-2-yl-3,6-dihydro-2H-pyridin-1-ylmethyl)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
- (519. (original) A compound according to claim 1, wherein said compound is 2-[4-(5-fluorobenzo[b]thiophen-3-yl)-3,6-dihydro-2H-pyridin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
- (b) 20. (original) A compound according to claim 1, wherein said compound is 2-[4-(7-methoxy-benzofuran-3-yl)-3,6-dihydro-2H-pyridin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
- (7) 21. (original) A compound according to claim 1, wherein said compound is 2-[4-(5-fluorobenzo[b]thiophen-3-yl)-3,6-dihydro-2H-pyridin-1-ylmethyl]-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.

Docket No.: AM101204 US/WYNC-0328

Application No.: 10/659,160

Office Action Dated: November 24, 2004

- 18 22. (original) A compound according to claim 1, wherein said compound is 2-(4-benzo[b]thiophen-3-yl-3,6-dihydro-2H-pyridin-1-ylmethyl)-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
 - 23. (withdrawn) A compound according to claim 1, wherein said compound is 2-(4-benzo[b]thiophen-3-yl-3,6-dihydro-2H-pyridin-1-ylmethyl)-2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole or a pharmaceutically acceptable salt thereof.
 - 24. (withdrawn) A compound according to claim 1, wherein said compound is 2-[4-(5-fluoro-benzo[b]thiophen-3-yl)-3,6-dihydro-2H-pyridin-1-ylmethyl]-2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole or a pharmaceutically acceptable salt thereof.
 - 25. (withdrawn) A compound according to claim 1, wherein said compound is 8-(4-benzo[b]thiophen-3-yl-3,6-dihydro-2H-pyridin-1-ylmethyl)-2-methyl-7,8-dihydro-[1,4]dioxino[2,3-g][1,3]benzoxazole or a pharmaceutically acceptable salt thereof.
- 19 26. (original) A compound according to claim 1, wherein said compound is 2-(4-benzo[b]thiophen-7-yl-3,6-dihydro-2H-pyridin-1-ylmethyl)-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
- >0 27. (original) A compound according to claim 1, wherein said compound is 2-(4-benzofuran-2-yl-3,6-dihydro-2H-pyridin-1-ylmethyl)-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
- 28. (original) A compound according to claim 1, wherein said compound is 2-(4-benzofuran-2-yl-piperidin-1-ylmethyl)-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
- > 2.29. (original) A compound according to claim 1, wherein said compound is 2-[4-(5-chlorobenzo[b]thiophen-3-yl)-3,6-dihydro-2H-pyridin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.

Docket No.: AM101204 US/WYNC-0328

Application No.: 10/659,160

Office Action Dated: November 24, 2004

2.3 30. (original) A compound according to claim 1, wherein said compound is 2-(4-benzoxazol-2-yl-piperidin-1-ylmethyl)-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.

- enantiomer, substantially free of the R enantiomer of said compound.
- A method of treating a subject suffering from a condition selected from depression, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obsessive, eating disorders, vasomotor premature ejaculation flushing, cocaine and alcohol addiction, and sexual-dysfunction, comprising the step of:

administering to said subject suffering from said condition, a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

- 27 33. (withdrawn) A method according to claim 32, wherein the condition is depression.
- A method according to claim 32, wherein the condition is selected from the group consisting of obsessive compulsive disorder, panic attacks, generalized anxiety disorder, and social anxiety disorder.
- 25 35. (original) A pharmaceutical composition, comprising:

an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable carrier or excipient.